A recombinant myxoma virus expressing p14 FAST targets cancer cells with deficient innate anti-viral responses to induce apoptosis.
Optimized lentiviral transduction protocols reduce toxic adjuvant requirements while maintaining high vector copy numbers in hematopoietic stem cells.
Replacing negatively charged phospholipids with neutral or cationic compounds enables effective cationic lipid incorporation for genetic material binding.